GB2553685B - Novel ethynylxanthines for use as inhibitors of matrix metalloproteinases and angiogenesis - Google Patents

Novel ethynylxanthines for use as inhibitors of matrix metalloproteinases and angiogenesis Download PDF

Info

Publication number
GB2553685B
GB2553685B GB1714549.1A GB201714549A GB2553685B GB 2553685 B GB2553685 B GB 2553685B GB 201714549 A GB201714549 A GB 201714549A GB 2553685 B GB2553685 B GB 2553685B
Authority
GB
United Kingdom
Prior art keywords
ethynylxanthines
angiogenesis
inhibitors
novel
matrix metalloproteinases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB1714549.1A
Other versions
GB2553685A8 (en
GB2553685A (en
Inventor
Arsenjans Pavels
Kauss Valerjans
Vasiljeva Jelena
Kalvins Ivars
Domracheva Ilona
Shestakova Irina
Gulbe Anita
Kanepe-Lapsa Iveta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Latvian Institute of Organic Synthesis
Original Assignee
Latvian Institute of Organic Synthesis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Latvian Institute of Organic Synthesis filed Critical Latvian Institute of Organic Synthesis
Publication of GB2553685A publication Critical patent/GB2553685A/en
Publication of GB2553685A8 publication Critical patent/GB2553685A8/en
Application granted granted Critical
Publication of GB2553685B publication Critical patent/GB2553685B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
GB1714549.1A 2015-03-27 2015-03-27 Novel ethynylxanthines for use as inhibitors of matrix metalloproteinases and angiogenesis Active GB2553685B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/LV2015/000002 WO2016159746A1 (en) 2015-03-27 2015-03-27 Novel ethynylxanthines, their preparation and use as inhibitors of matrix metalloproteinases and angiogenesis

Publications (3)

Publication Number Publication Date
GB2553685A GB2553685A (en) 2018-03-14
GB2553685A8 GB2553685A8 (en) 2018-04-18
GB2553685B true GB2553685B (en) 2020-06-10

Family

ID=52815228

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1714549.1A Active GB2553685B (en) 2015-03-27 2015-03-27 Novel ethynylxanthines for use as inhibitors of matrix metalloproteinases and angiogenesis

Country Status (2)

Country Link
GB (1) GB2553685B (en)
WO (1) WO2016159746A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004007469A1 (en) * 2002-07-12 2004-01-22 Warner-Lambert Company Llc New alkynylated quinazolin compounds as mmp-13 inhibitors
WO2004014916A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
WO2008077557A1 (en) * 2006-12-22 2008-07-03 Schwarz Pharma Ag 8-ethinylxanthine derivatives as selective a2a receptor antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2166948C1 (en) 2000-05-29 2001-05-20 Центральный научно-исследовательский рентгенорадиологический институт Method for treating gliomae aggravated with epileptic syndrome
US8435541B2 (en) 2010-09-02 2013-05-07 Bath & Body Works Brand Management, Inc. Topical compositions for inhibiting matrix metalloproteases and providing antioxidative activities
HUE033528T4 (en) 2013-03-15 2018-05-02 Hydra Biosciences Inc Substituted xanthines and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004007469A1 (en) * 2002-07-12 2004-01-22 Warner-Lambert Company Llc New alkynylated quinazolin compounds as mmp-13 inhibitors
WO2004014916A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
WO2008077557A1 (en) * 2006-12-22 2008-07-03 Schwarz Pharma Ag 8-ethinylxanthine derivatives as selective a2a receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE REGISTRY [ONLINE] CHEMICAL ABSTRACTS SERVICE COLUMBUS OHIO 12/06/2006 *

Also Published As

Publication number Publication date
WO2016159746A1 (en) 2016-10-06
GB2553685A8 (en) 2018-04-18
GB2553685A (en) 2018-03-14

Similar Documents

Publication Publication Date Title
ZA201700304B (en) Spirocycloheptanes as inhibitors of rock
IL251584A0 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
IL246902B (en) Dihydropyrrolopyridine inhibitors of ror-gamma
IL248505B (en) Inhibitors of lysine specific demethylase-1
IL249733B (en) Inhibitors of lysine specific demethylase-1
ZA201704382B (en) 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of parg
HUE058852T2 (en) Inhibitors of lysine specific demethylase-1
SG11201708027XA (en) Compounds and their use as bace1 inhibitors
IL257061A (en) Inhibitors of ezh2
GB201521059D0 (en) Inhibitors of metallo-beta-lactamases
PL3313833T3 (en) Compounds and their use as inhibitors of n-myristoyl transferase
HUE044559T2 (en) Scale inhibitor compositions and methods of using
GB2553685B (en) Novel ethynylxanthines for use as inhibitors of matrix metalloproteinases and angiogenesis
GB201521541D0 (en) New therapeutic uses of enzyme inhibitors
GB201521547D0 (en) New therapeutic uses of enzyme inhibitors
GB201421812D0 (en) New therapeutic uses of enzyme inhibitors
GB201410529D0 (en) New therapeutic uses of enzyme inhibitors
TH1601000084A (en) Method and composition of granulation formula